Inventiva (NASDAQ:IVA – Free Report) had its price target lowered by Stifel Nicolaus from $25.00 to $20.00 in a report published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.
Inventiva Stock Up 2.8 %
IVA stock opened at $1.84 on Thursday. Inventiva has a 12 month low of $1.53 and a 12 month high of $4.75. The firm’s fifty day simple moving average is $2.25 and its 200-day simple moving average is $2.96.
Hedge Funds Weigh In On Inventiva
A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors.
Inventiva Company Profile
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Read More
- Five stocks we like better than Inventiva
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Best Stocks Under $10.00
- MarketBeat Week in Review – 9/23 – 9/27
- Do ETFs Pay Dividends? What You Need to Know
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
